Major victory for global pharmaceutical company

Government_4.jpg

When two leading Australian generic drug manufacturers challenged the patent for the antidepressant, Lexapro, the landmark Australian case raised questions of chemistry, regulatory data and patent term extensions.

Corrs represented patent owner Lundbeck, a major global pharmaceutical company based in Denmark. Our work required close collaboration with the in-house counsel of the Danish research company, US and British lawyers to co-ordinate strategy and the use of expert witnesses in more than one jurisdiction to secure a victory in the only case of its kind upheld by Australian Courts.